Regulatory Activities: In April 2025, Sanofi and Regeneron Pharma received approval from the U.S. FDA for Dupixent (dupilumab) to treat adults and adolescents aged 12 years and older with chronic ...

The recent executive orders on pharma issued by President Donald Trump are expected to create significant challenges for ...